Transcatheter mitral valve interventions

Resor, Charles D.

doi:10.1016/j.pcad.2021.11.005

Cited by 1 publication

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, for the MITRAL trial, the mortality at 1 year was 3.3% (unchanged from 30-day outcomes) and 6.7% at 2 and 3 years [36]. Based on the available data, MViV was, thus, FDA approved for high-risk patients in June 2017 [38], but is actively being investigated in the ongoing PARTNER 3 trial for intermediate-surgical-risk patients, which consists of a prospective registry of 50 patients at 16 sites in the United States and Canada that recently completed enrollment in 2021 [39].…”

Section: Valve In Valvementioning

confidence: 99%

See 1 more Smart Citation

Contemporary Review of Transcatheter Mitral Valve Interventions for Mitral Regurgitation

Chan

Dong

Sabbak

et al. 2023

Life

View full text Add to dashboard Cite

Mitral regurgitation (MR) is the most common form of valvular heart disease in the United States, and there are established guidelines for indications for requiring mitral valve surgeries. However, there is an unmet clinical need for a subset of high-risk MR patients, especially those with advanced age, heart failure and/or secondary MR. Following the successes of transcatheter aortic valve replacements, significant advances have occurred over the last decade in transcatheter mitral valve interventions in order to manage these patients in both clinical practice and trials. The three main types of these interventions include a transcatheter edge-to-edge repair, percutaneous mitral annuloplasty (both direct and indirect) and transcatheter mitral valve replacement (including when applied to a prior prosthetic valve, annuloplasty ring and mitral annuloplasty ring). This review aims to discuss the contemporary techniques, evidence, indications, multimodality imaging evaluations and outcomes of the various transcatheter mitral valve interventions.

show abstract

Section: Valve In Valvementioning

confidence: 99%

“…The access route was also switched from being mainly transapical to transeptal. Based on these data, the FDA approved MViR for high-risk patients in May 2021 [38].…”

Section: Valve In Ringmentioning

confidence: 99%